Abstract
Objective Myositis-specific autoantibodies (MSAs) define distinct clinical subsets of idiopathic inflammatory myopathies (IIMs). The anti-nuclear matrix protein 2 (NXP2) antibody, a MSA detected in juvenile/adult IIMs, has been reported to be associated with a high risk of subcutaneous calcinosis, subcutaneous edema, and internal malignancies. The study aimed to clarify the clinical features of anti-NXP2 antibody-positive IIMs in detail.
Methods This multi-center retrospective observational study on 76 anti-NXP2 antibody-positive patients. The antibody was detected via a serological assay using immunoprecipitation and western blotting. The patients were selected from 162 consecutive Japanese patients with IIMs.
Results The cohort of anti-NXP2 antibody-positive IIMs included 29 juvenile patients and 47 adult patients. Twenty-seven (35.5%) patients presented with polymyositis phenotype without dermatomyositis-specific skin manifestations (heliotrope rash and Gottron sign/papules); this was more common in the adults than children (48.9% vs. 15.8%, P < 0.01). Nine (11.8%) patients had subcutaneous calcinosis, and 20 (26.3%) patients had subcutaneous edema. In addition, the proportion of patients with muscle weakness extending to the distal limbs was high (36 patients [47.4%]) in this cohort. Adult patients had a higher prevalence of malignancy than the general population (age-standardized incidence ratio of malignancies: 22.4).
Conclusion Anti-NXP2 antibody-positive IIMs, which include dermatomyositis sine dermatitis, are characterized by atypical skin manifestations and extensive muscular involvement.
Competing Interest Statement
Masaaki Mori: Grant from Chugai Pharmaceutical Co., Ltd., UCB Japan Co. Ltd., CSL Behring, Abbvie Japan Co., Ltd., Japan Blood Products Organization, Ayumi Pharmaceutical Co., Nippon Kayaku Co., Ltd, Asahikasei Pharmaceutical Co.; Consulting fees from Daiichi Sankyo Co., Ltd. and Taisho Pharmaceutical Co., Ltd.; and lecture fees from SD K.K.
Funding Statement
Supported by KAKENHI from the Japan Society for the Promotion of Science (JSPS, 18K08263 for Naoko Okiyama).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the ethics committee of University of Tsukuba Hospital (H29-111) in accordance with the Helsinki Declaration.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding Supported by KAKENHI from the Japan Society for the Promotion of Science (JSPS, 18K08263 for Naoko Okiyama).
Competing interests MM: Grant from Chugai Pharmaceutical Co., Ltd., UCB Japan Co. Ltd., CSL Behring, Abbvie Japan Co., Ltd., Japan Blood Products Organization, Ayumi Pharmaceutical Co., Nippon Kayaku Co., Ltd, Asahikasei Pharmaceutical Co.; Consulting fees from Daiichi Sankyo Co., Ltd. and Taisho Pharmaceutical Co., Ltd.; and lecture fees from SD K.K.
Data Availability
This manuscript does not include a data set that requires deposition.
